Cel Sci CVM
NYSE CVM
$2.04 +0.25 (+13.97%)
As of: Sep 30, 2026 · 3:58 PM EDT

Cel Sci (CVM) EBITDA Margin (2010 - 2017)

Updated

Cel Sci (CVM) recorded EBITDA Margin of -26459.10% in fiscal Q3 2017 (quarter ended Jun 30, 2017), down 22042.70 percentage points from -4416.41% a year earlier.

Analysis

Cel Sci (CVM) EBITDA Margin (2010 - 2017) Analysis & Trends

On a TTM basis, Cel Sci's EBITDA Margin came in at -9232.29% as of Jun 30, 2017.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 35.95%
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 49.01%
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 6.02%
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 33.11%
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 46.01%
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 39.10%
10 Cel Sci 3.22 Mn -22.43 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 -26,459.10%
Jun 30, 2016 -4,416.41%
Jun 30, 2011 -6,069.01%
Jun 30, 2010 -10,548.50%
API Access

Cel Sci EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CVM&period=max&api_key=YOUR_API_KEY